Condition

Carcinoma, Transitional Cell (1)

Renal Pelvis Neoplasms (1)

Ureteral Neoplasms (1)

Urethral Neoplasms (1)

Urinary Bladder Neoplasms (1)

Urologic Neoplasms (1)

Urothelial Cancer (1)

Overall Status

Active, not recruiting (1)

Sign in for free

Phase

phase 1/phase 2 (1)

Sponsor

Astellas Pharma Global Development, Inc. (1)

Collaborator

Merck Sharp & Dohme LLC (1)

Seagen Inc. (1)

Intervention

carboplatin (1)

cisplatin (1)

enfortumab vedotin (ev) (1)

gemcitabine (1)

pembrolizumab (1)

Study Documents

Intervention Type

drug (1)

Funder Type

Industry (1)

Study Type

Interventional (1)

renal pelvis neoplasms

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Carcinoma, Transitional Cell, Urinary Bladder Tumors, Urologic Tumors Trial in Worldwide (enfortumab vedotin (EV),

Active, not recruiting

Carcinoma, Transitional Cell
+6 more

enfortumab vedotin (EV)
+4 more

Anchorage, Alaska
+105 more

Dec 19, 2022